Chief Development Officer Scout Bio Philadelphia, Pennsylvania, United States
AAV Gene Therapy is an exciting new field in human medicine. Although human medicine has focused on rare genetic diseases, there is promise for vectored therapeutics to be used as a new modality in treating chronic acquired diseases in companion animals. We will discuss the history of gene therapy and how dogs and cats have supported recent human drug approvals. The mechanism will be explained and examples of recent data in clinical veterinary patients will be discussed.
Learning Objectives:
Attendees will be able to answer: How do AAV vectors allow a single injection to provide a therapeutic protein to a patient fo long term therapy, potentially years?
Attendees will be able to answer: How long have AAV gene therapies been studied?
Attendees will be able to answer: What diseases in animal health may be good candidate for AAV vectored?
.png)
